Identification of ZBTB9 as a potential therapeutic target against dysregulation of tumor cells proliferation and a novel biomarker in Liver Hepatocellular Carcinoma

Table 4 Univariable and multivariable analysis of ZBTB9 associated with OS, and the unknown data in each group were excluded before multivariate analysis

Characteristics	Total (N)	Univariate analysis		Multivariate analysis
Characteristics	Total (N)	Hazard ratio (95% CI)	P. value	Hazard ratio (95% CI)	P. value
T stage	370
T1 & T2	277	1.000		1.000
T3 & T4	93	2.598 (1.826–3.697)	< 0.001	1.531 (0.208–11.249)	0.676
N stage	258
N0	254	1.000
N1	4	2.029 (0.497–8.281)	0.324
M stage	272
M0	268	1.000
M1	4	4.077 (1.281–12.973)	0.017	1.262 (0.301–5.302)	0.750
Gender	373
Female	121	1.000
Male	252	0.793 (0.557–1.130)	0.200
Pathologic stage	349
I & II	259	1.000		1.000
III & IV	90	2.504 (1.727–3.631)	< 0.001	1.610 (0.220–11.798)	0.639
Race	361
Asian	159	1.000
White	185	1.323 (0.909–1.928)	0.144
Black or African American	17	1.585 (0.675–3.725)	0.290
Residual tumor	344
R0	326	1.000
R1&R2	18	1.604 (0.812–3.169)	0.174
BMI	336
≤ 25	177	1.000
\(>\) 25	159	0.798 (0.550–1.158)	0.235
AFP (ng/ml)	279
≤ 400	215	1.000
> 400	64	1.075 (0.658–1.759)	0.772
Vascular invasion	317
No	208	1.000
Yes	109	1.344 (0.887–2.035)	0.163
Histologic grade	368
G1	55	1.000
G2	178	1.162 (0.686–1.969)	0.576
G3	123	1.185 (0.683–2.057)	0.545
G4	12	1.681 (0.621–4.549)	0.307
Age	373
≤ 60	177	1.000
> 60	196	1.205 (0.850–1.708)	0.295
Tumor status	354
Tumor free	202	1.000		1.000
With tumor	152	2.317 (1.590–3.376)	< 0.001	1.854 (1.156–2.975)	0.010
ZBTB9	373
Low	186	1.000		1.000
High	187	1.848 (1.291–2.644)	< 0.001	1.779 (1.125–2.812)	0.014

ISSN: 1479-5876